25(OH)D Is Effective to Repress Human Cholangiocarcinoma Cell Growth through the Conversion of 25(OH)D to 1α,25(OH)2D3
Authors:
- Kun-Chun ChiangKCKun-Chun Chiang
- Chun-Nan YehCYChun-Nan Yeh
- Cheng-Cheng HuangCHCheng-Cheng Huang
- Ta-Sen YehTYTa-Sen Yeh
- Jong-Hwei S. PangJPJong-Hwei S. Pang
- Jun-Te HsuJun-Te Hsu
- Li-Wei ChenLCLi-Wei Chen
- Sheng-Fong KuoSKSheng-Fong Kuo
- Atsushi KittakaAKAtsushi Kittaka
- Tai C. ChenTCTai C. Chen
- Horng-Heng JuangHJHorng-Heng Juang
Open Access
- 12 August 2016
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (8) , 1326
Abstract
Cholangiocarcinoma (CCA) is a devastating disease without effective treatments. 1α,25(OH)2D3, the active form of Vitamin D, has emerged as a new anti-cancer regimen. However, the side effect of hypercalcemia impedes its systemic administration. 25(OH)D is biologically inert and needs hydroxylation by CYP27B1 to form 1α,25(OH)2D3, which is originally believed to only take place in kidneys. Recently, the extra-renal expression of CYP27B1 has been identified and in vitro conversion of 25(OH)D to 1α,25(OH)2D3 has been found in some cancer cells with CYP27B1 expression. In this study, CYP27B1 expression was demonstrated in CCA cells and human CCA specimens. 25(OH)D effectively represses SNU308 cells growth, which was strengthened or attenuated as CYP27B1 overexpression or knockdown. Lipocalcin-2 (LCN2) was also found to be repressed by 25(OH)D. After treatment with 800 ng/mL 25(OH)D, the intracellular 1α,25(OH)2D3 concentration was higher in SNU308 cells with CYP27B1 overexpression than wild type SNU308 cells. In a xenograft animal experiment, 25(OH)D, at a dose of 6 μg/kg or 20 μg/kg, significantly inhibited SNU308 cells’ growth without inducing obvious side effects. Collectively, our results indicated that SNU308 cells were able to convert 25(OH)D to 1α,25(OH)2D3 and 25(OH)D CYP27B1 gene therapy could be deemed as a promising therapeutic direction for CCA.Keywords
Funding Information
- Ministry of Science and Technology) (103-2314-B-182A-085 - and 104-2314-B-182A-017 –)
- Chang Gung Memorial Hospita (CMRPG2D0191, 0192, and 0193)
This publication has 32 references indexed in Scilit:
- Vitamin D for the prevention and treatment of pancreatic cancerWorld Journal of Gastroenterology, 2009
- Vitamin D signalling pathways in cancer: potential for anticancer therapeuticsNature Reviews Cancer, 2007
- The Epidemiology of CholangiocarcinomaSeminars in Liver Disease, 2004
- Pancreatic cancer cells express 25-hydroxyvitamin D-1 -hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3Carcinogenesis, 2004
- Cholangiocarcinoma: Current Concepts and InsightsHepatology, 2003
- 25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transferThe Journal of Steroid Biochemistry and Molecular Biology, 2002
- Extrarenal Expression of 25-Hydroxyvitamin D3-1 -HydroxylaseThe Journal of Clinical Endocrinology & Metabolism, 2001
- Sunlight and Breast Cancer Incidence in the USSRInternational Journal of Epidemiology, 1990
- Neonatal human foreskin keratinocytes produce 1,25-dihydroxyvitamin D3Biochemistry, 1986
- Do Sunlight and Vitamin D Reduce the Likelihood of Colon Cancer?International Journal of Epidemiology, 1980